ISIS PHARMACEUTICAL (ISI BE) stock market data APIs
€50.8504
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
ISIS PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ISI.BE.
Prev. Close
50.8504
Open
50.8504
High
50.8504
Low
50.8504
52 wk Range
22.5-54.54
Market Cap
3 685 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ISIS PHARMACEUTICAL data using free add-ons & libraries
Get ISIS PHARMACEUTICAL Fundamental Data
ISIS PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ISIS PHARMACEUTICAL News
New
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
CARLSBAD, Calif., September 12, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease com...
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
PASADENA, Calif., September 11, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States ...
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis Pharmaceuticals IONS announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological d...
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
- Pivotal Phase 3 REVEAL study enrollment on track to complete in 2026 - CARLSBAD, Calif., September 09, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
